Purpose: To compare the potential application of 99m Tc-3P-Arg-Gly-Asp ( 99m Tc-3P 4 -RGD 2 ) scintimammography (SMM) and 99m Tc-methoxyisobutylisonitrile ( 99m Tc-MIBI) SMM for the differentiation of malignant from benign breast lesions.
Introduction
Breast cancer continues to be a major public health problem all over the world. The American Cancer Society estimates that there will be about 296,980 new cases of breast cancer in 2013, which is expected to account for 14% of female cancer deaths.
A realistic strategy for the reduction of breast cancer mortality rates and timely treatment is to detect the disease while it is still in an early stage. [1, 2] . The most common screening method for early breast cancer is mammography, which is very sensitive in the detection of malignant breast disease. However in several groups of breast cancer patients, including those with fibroadenoma breasts, post implants, mastectomy or severe dysplasia, mammography has a low predictive value (20%-30%) and is not accurate, requiring patients to undergo histopathological examinations for a definitive diagnosis [3, 4] . To improve diagnostic accuracy, new methods are being studied as alternatives to mammography. Over the last twenty years, Scintimammography (SMM) has been introduced as an adjunct modality to present imaging modalities for breast cancer imaging [5] . In addition to the imaging modality, several radiopharmaceuticals have also been investigated for diagnostic imaging procedures in patients with suspected breast cancer [6] . 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) [7] is proven to be the most effective in detection of breast cancer for diagnosis, staging and restaging, but its use is limited by the high cost of equipment and lack of general availability, especially in developing countries. Alternatively, single photon emission computed tomography (SPECT) is more widely used with a much lower cost worldwide.
99m Tc-methoxyisobutylisonitrile ( 99m Tc-MIBI) is an important tracer for oncological applications and has been widely used in breast tumor imaging. However, this tracer originated from nuclear medicine for cardiac imaging and was not specifically designed for tumor imaging. The exact mechanism of uptake in breast cancer cells is still not entirely clear. It is reported that 99m Tc-MIBI is concentrated in cancer cells by an energy-requiring transport mechanism, specifically by transmembrane electrical potentials, as well as by non-specific mechanisms, and the tracer is stored within the mitochondria [8] .
It is well documented that integrin avb3 plays a critical role in the regulation of tumor angiogenesis and metastasis [9, 10] . The integrin is upregulated on activated endothelial cells and is highly expressed in tumor cells of various tumor types, including breast cancer [11, 12] . Over the past decade, radiolabeled Arg-Gly-Asp (RGD) peptides and analogs that specifically target integrin avb3 have been intensively investigated for noninvasive imaging of tumors in pre-clinical and clinical studies [13] [14] [15] [16] [17] [18] [19] . We previously developed the avb3-specific tracer 99m Tc-3P-Arg-Gly-Asp ( 99m Tc-3P 4 -RGD 2 ) for SPECT and already demonstrated that 99m Tc-3P 4 -RGD 2 SPECT allows specific imaging of avb3 expression with high accuracy in detecting malignant solitary pulmonary nodules (SPNs), esophageal cancer, and malignant gliomas [20] [21] [22] .
In this study, we compare the diagnostic value of 99m Tc-3P 4 -RGD 2 SMM with 99m Tc-MIBI SMM for the detection of breast cancer by receiver operating characteristic (ROC) curve analysis.
Materials and Methods

Patients
Thirty-six patients with breast masses on physical examination and/or suspicious mammographic findings that required fine needle aspiration cytology biopsy (FNAB) were included in this study. The patient mean age was 41 
Scintimammography protocol
Radiolabeling and quality control procedures for 3P 4 -RGD 2 were performed as described previously [20] . Both 3P 4 [23, 24] .
99m Tc-3P 4 -RGD 2 and 99m Tc-MIBI SMM were performed at 60 min and 20 min after intravenous injection, respectively. Patients were in supine position with raised arms during imaging.
SPECT was performed using a double-head c camera (Precedence, Philips Healthcare), equipped with low-energy parallel hole collimators. The matrix was 1286128 pixels, and the photopeak was centered at 140 keV with a symmetrical 20% window. Imaging with both radiotracers was performed using 6u angular steps in a 20 s time frame. Distance between the breast and detector was minimized.
Data analysis
Both 99m Tc-3P 4 -RGD 2 and 99m Tc-MIBI SMM uptake were evaluated by semiquantitative analysis. Regions of interest (ROIs) were drawn around the tumor and an area of normal breast tissue in the same breast on lateral images and used to determine the tumor to non-tumor ratios (T/NT) of 99m Tc-3P 4 -RGD 2 and 99m Tc-MIBI.
All numerical results are reported as mean values with standard deviations (SDs). Student's t test was used for statistical comparison of quantitative indices between the malignant and benign breast disease groups. The IBM SPSS Statistics19 software was used to determine cut-off values of quantitative indices in the detection of primary breast cancer. The incremental diagnostic value of quantitative indices analysis was performed using calculated areas under the curve (AUCs) in ROC analysis. Statistical significance was defined as p,0.05.
Results
Samples for histological examination were obtained by surgery in 28 patients and by core needle biopsy in eight patients. Breast cancer was confirmed in 26 patients and resulted in a total of 28 cancer lesions with diameters ranging from 0.3 cm to 7.9 cm (mean 6 SD: 2.8661.73 cm). Benign breast disease was found in 10 patients with a total of 11 benign lesions ranging in diameter from 0.4 cm to 6.5 cm (mean 6 SD: 2.8361.91 cm). In this study, the yielding breast cancer prevalence was 71.8% (Table 2) .
We observed high 99m Tc-3P 4 -RGD 2 uptake in breast cancer and low 99m Tc-3P 4 -RGD 2 uptake in benign lesions (Fig. 1A) . In 99m Tc-3P 4 -RGD 2 SMM, the T/NT of breast cancer was 3.5461.51 and that of benign lesions was 1.8360.98. The difference was statistically significant (p,0.001). Similarly in 99m Tc-MIBI SMM, high MIBI uptake was observed in breast cancer while low MIBI uptake was detected in benign lesions (Fig. 2) . 99m Tc-MIBI SMM was false positive in 3 benign lesions. Of the false positive cases, two were fibroadenoma and one was fibroadenoma with mastitis. The fibroadenoma with mastitis was also false positive in 99m Tc-3P 4 -RGD 2 SMM (Fig. 3) .
ROC analyses were performed to determine the optimal cut-off values of both 99m Tc-3P 4 -RGD 2 and 99m Tc-MIBI SMM T/NT for the detection of malignant breast cancer. When a cut-off value was used based on the ROC analysis, the sensitivity, specificity and accuracy of 99m Tc-3P 4 -RGD 2 SMM were 89.3%, 90.9% and 89.7%, respectively (cutoff = 2.40 of T/NT), and those of 99m Tc-MIBI SMM were 87.5%, 72.7% and 82.1%, respectively (cutoff = 1.46 of T/NT). The empirical ROC areas, which estimate the overall diagnostic performance, did not differ significantly among the two diagnostic analyses (Fig. 4) 
Discussion
Over the last twenty years, SMM has been proposed to be a complementary tool to mammography in the diagnosis of primary breast cancer [5] . An already widely used radiopharmaceutical, 99m Tc-MIBI appears to be a suitable SMM scanning agent. Many publications have reported favorable sensitivity and specificity results, 84%-96% and 72%-94%, respectively, for 99m Tc-MIBI scintigraphy in the diagnosis of breast cancer [25] [26] [27] [28] [29] [30] [31] [32] .
99m Tc-3P 4 -RGD 2 is a new agent with a high affinity for the avb3 integrin, a receptor associated with angiogenesis. In our previous study, we found that 99m Tc-3P 4 -RGD 2 could accumulate in a variety of malignant lesions [20] [21] [22] . However, a comparative study between 99m Tc-3P 4 -RGD 2 and 99m Tc-MIBI SMM has not been previously reported.
In this present study, to differentiate benign from malignant lesions, ROC analyses were performed to determine the optimal cut-off values of T/NT of 99m Tc-3P 4 -RGD 2 and 99m Tc-MIBI SMM. When T/NT of 2.40 was used as a cut-off point, the sensitivity, specificity and accuracy of 99m Tc-3P 4 -RGD 2 SMM were 89.3%, 90.9% and 89.7%, respectively. With a T/NT of 1.45 as a cut-off value, the same findings were 87.5%, 72.7% and 82.1% in 99m Tc-MIBI SMM, respectively. The sensitivities reported in this study for 99m Tc-3P 4 -RGD 2 SMM are comparable with our previous reports; however the specificity is slightly higher than previous studies, which may be due to the low total number of benign breast lesions [20] [21] [22] . For 99m Tc-MIBI SMM, the results reported here are comparable with those in previous studies [25] [26] [27] [28] [29] [30] [31] [32] . Although the sensitivity, specificity and accuracy of 99m Tc-3P 4 -RGD 2 SMM was slightly superior to that of 99m Tc-MIBI SMM in this study, the difference was not statistically significant. The area under the curve of 99m Tc-3P 4 -RGD 2 SMM was slightly larger than that of 99m Tc-MIBI SMM, although this difference was also not significant.
It is generally accepted that the detection sensitivity of SMM is much lower for small breast cancer lesions with a diameter less than 1 cm over larger lesions [29] . Data from a multicentre European study showed a sensitivity of 26%-56% for lesions less than 1 cm [33] . Similarly in the present study, neither 99m Tc-3P 4 -RGD 2 nor 99m Tc-MIBI was sufficient to visualize tumors in three patients having malignant lesions with diameters at 0.3 cm, 0.4 cm and 0.6 cm, respectively. The 99m Tc-3P 4 -RGD 2 and 99m Tc-MIBI uptake in small lesions is considered to be underestimated due to partial volume effects from the relatively low spatial resolution of the SPECT device, though other factors such as the degree of radiopharmaceutical uptake by tumors and normal breast tissue may have contributed as well.
In one case of DCIS with a long axis diameter of 2.2 cm was false negative on 99m Tc-MIBI SMM but not 99m Tc-3P 4 -RGD 2 SMM. Some reports state that 99m Tc-MIBI SMM always showed a low sensitivity for detecting DCIS. Vassilios Papantoniou et al. [34] studied the diagnostic accuracy of 99m Tc-MIBI SMM in 13 cases of DCIS and achieved a low sensitivity of 46%. Reinhard Obwegeser et al. [35] reported that 99m Tc-MIBI SMM could not detect all four DCIS in their study. They conceived it may be due to the histological type of DCIS, which is known to show a lower density of tumor cells per square unit than invasive ductal carcinomas. Conversely, experimental studies using in vivo assays have shown that breast carcinoma in situ may be antigenic [36] . Sections stained for endothelial markers have shown increased vascularity around DCIS [37] [38] [39] . A more detailed study demonstrated two patterns of increased vascularity: cuffs of vessels close to the involved ducts and vessels diffusely arranged in the interductal stroma [40] . The true positive result with 99m Tc-3P 4 -RGD 2 SMM in this common malignant tumor may be an advantage of RGD targeting. Further studies with a larger patient population is needed to determine this issue.
Three of the 11 patients with fibroadenoma showed focal 99m Tc-MIBI uptake, and one patient from this group who was diagnosed with fibroadenoma with severe mammitis on histopathological examination showed high focal tracer accumulation of 99m Tc-3P 4 -RGD 2 . The false positive results obtained with 99m Tc-MIBI in three fibroadenoma may be due to the high cellular activity associated in fibroadenoma. Previous studies have demonstrated that integrin avb3 is preferentially expressed on several types of cancer cells including melanoma, glioma, and ovarian and breast cancer. However, because expression is very low in existing blood vessels and absent in normal tissue, the accumulation of 99m Tc-3P 4 -RGD 2 may be mainly due to its higher specificity [41] [42] [43] [44] . As is known to all, inflammation was different from other benign lesions, always showed high cell density and vascularity, likely responsible for the increased uptake. Previous studies have also shown that the integrin avb3 can exist on neutrophils, monocytes, and vascular smooth muscle cells [45] , which can be the main reason for the false positive result using 99m Tc-3P 4 -RGD 2 SMM.
In 
